tbuckley/cabot-search huggingface dataset:
ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA
Authors: Michael Weller, Nicholas Butowski, David Tran, Lawrence Recht, Michael Lim, Hal Hirte, Lynn Ashby, Lazlo Mechtler, Samuel Goldlust, Fabio Iwamoto, Jan Drappatz, Donald O’Rourke, Mark Wong, Gaetano Finocchiaro, James Perry, Wolfgang Wick, Yi He, Thomas Davis, Roger Stupp, John Sampson
Journal: Neuro-Oncology (2016)

The EGFR deletion mutation, EGFRvIII, is expressed in ~30% of glioblastomas (GBM). The EGFRvIII-targeted vaccine rindopepimut consists of EGFRvIII peptide conjugated to keyhole limpet hemocyanin (KLH). A survival benefit was observed in a randomized phase 2 trial of recurrent GBM (ReACT; n=73). In three phase 2 studies of 105 total patients with newly diagnosed, EGFRvIII+ GBM and minimal residual disease (MRD), the median overall survival (mOS) was 20–22 months, as compared to ~16 months for two matched contemporary datasets (n=16, n=29). Patients with newly diagnosed, resected, EGFRvIII+ GBM were, after standard chemoradiation, stratified by RPA class, MGMT promoter methylation, and geographic region, and randomized (1:1) to double-blind rindopepimut or control (KLH) concurrent with standard maintenance temozolomide. Primary endpoint is OS for MRD patients (enhancing tumor <2 cm2 post-chemoradiation by central review) aiming to detect hazard ratio (HR) ≤0.71 with 80% power and alpha=0.05 (log-rank test). Interim analyses were preplanned at 50% and 75% of events. Secondary analyses included patients with ≥2 cm2 of residual tumor (non-MRD). 745 patients (405 MRD) were enrolled at 165 centers. The study was terminated for futility after the 2nd interim analysis (MRD OS HR=0.99). At final analysis, mOS for rindopepimut vs. control was 20.1 vs. 20.0 (HR=1.01; p=0.93) in the MRD cohort, and 14.8 vs. 14.1 (HR=0.79; p=0.066) with 2-year OS 30% vs. 19% in the non-MRD cohort. There were no substantial differences in progression-free survival. Rindopepimut was well tolerated (chief toxicity: injection site reaction) with robust anti-EGFRvIII immune response. The study failed to demonstrate a survival benefit for patients treated with rindopepimut and standard chemotherapy. Rindopepimut OS is comparable to prior studies, however, patients in the control arm fared better than historical controls. A trend for long-term survival benefit in non-MRD patients suggests a preferential effect in bulkier disease.
Safety and Efficacy of ThaDD Regimen in Very Elderly Patients with Multiple Myeloma (MM)
Authors: Massimo Offidani, Laura Corvatta, Maria-Novella Piersantelli, Claudia Polloni, Silvia Gentili, Piero Galieni, Giuseppe Visani, Francesco Alesiani, Massimo Catarini, Marino Brunori, Arduino Samori, Maurizio Burattini, Riccardo Centurioni, Mario Ferranti, Luciano Giuliodori, Marco Candela, Monica Marconi, Anna Mele, Pietro Leoni
Journal: Blood (2008)
Current status and outcomes of salvage radiotherapy for patients with PSA recurrence after prostatectomy: A JROSG surveillance study.
Authors: Takashi Mizowaki, Manabu Aoki, Katsumasa Nakamura, Atsunori Yorozu, Masaki Kokubo, Katsuyuki Karasawa, Takuyo Kozuka, Nobuaki Nakajima, Keisuke Sasai, Tetsuo Akimoto
Journal: Journal of Clinical Oncology (2013)

207 Background: Salvage radiotherapy (S-RT) for patients with prostate cancer who developed PSA failure after radical prostatectomy is widely applied. However, current status of this approach in Japan has not been surveyed so far. The aim of this study was to reveal the present conditions and outcomes of S-RT for Japanese patients with biochemically recurrent prostate cancer. Methods: Clinical data of the S-RT was gathered by sending a questionnaire to participating facilities to the Japanese Radiation Oncology Study Group (JROSG). The S-RT was defined as external-beam radiotherapy delivered to the prostate bed to patients with prostate cancer who eventually developed PSA failure, although their PSA value had once reached &lt;0.2 ng/ml after prostatectomy. In addition, the interval between prostatectomy and the S-RT should essentially be six months or longer. PSA failure-free survival (PFFS) and clinical failure-free survival (CFFS) was calculated by the Kaplan-Meier estimation. Results: 371 cases were registered from 38 facilities. Among them, hormonal therapy was combined with S-RT in 151 patients. In 3 cases, chemotherapy was combined before or after the S-RT. The rests of the cases were treated by S-RT alone. However, prognostic information was insufficient in 28 cases, and PSA nadir was &gt;0.2 ng/ml in 3 cases. Therefore, outcome studies were conducted in the remaining 186 cases. The median age was 67 years old. The nadir value of the PSA after prostatectomy and the PSA value at the initiation of S-RT were 0.0135 ng/ml and 0.292 ng/ml, respectively. The median period between prostatectomy and the S-RT was 18.6 months. Median follow-up period was 58 months. The 5-year PFFS and CFFS were 50.1% (95%CI: 42.8 – 57.9) and 90.1% (95%CI: 86.4 – 95.7), respectively. PFFS was significantly superior in patients with PSA values &lt;= 0.3 ng/ml at the initiation of S-RT than those of PSA values &gt; 0.3. (57.5% vs. 40.5%, p = 0.027) Conclusions: In Japan, hormonal therapy was combined with S-RT in about 40% of the cases. The 5-year PFFS and CFFS rates of cases treated by S-RT alone were 50.1% and 90.1%, respectively. A PSA value of 0.3 was significant cut-off point for predicting PFFS.
Decitabine Or 5-Azacitidine Pre-Treatment Does Not Compromise The Novel Fc-Engineered Antibody Mab 33.1-Mediated ADCC Against Primary AML Blasts - A Rationale For Combination Therapy
Authors: Shun He, Carolyn Cheney, Susan P. Whitman, Jianhua Yu, Sumithira Vasu, William Blum, Karl-Heinz Heider, Guido Marcucci, Natarajan Muthusamy
Journal: Blood (2013)
Exogenous Apo-Transferrin Increases Monoferric Transferrin, Decreasing Cytosolic Iron Uptake and Heme and Globin Synthesis in β-Thalassemic Mice
Authors: Tenzin Choesang, Huihui Li, Michael Dussiot, Thiago Maciel, Laura Breda, Daniel Garcia Santos, Huiyong Chen, Maria Feola, Weili Bao, Petra Pham, Antonia Follenzi, Guiyuan Li, Ivan Cruz Moura, Prem Ponka, Robert E Fleming, Stefano Rivella, Yelena Ginzburg
Journal: Blood (2014)
Optimal Treatment for Patients after Dasatinib or Nilotinib: Comparison of Preclinical Activities of Approved and Promising Investigational Kinase Inhibitors Against BCR-ABL Kinase Domain Mutations That Confer Clinical Resistance to Dasatinib or Nilotinib.
Authors: Corynn Kasap, Christopher Weier, Neil P. Shah
Journal: Blood (2007)
Abstract 5568: Inhibitory Effect of Partial Electron Decoupling Agents as an Alternate Therapy for Cancer
Authors: Omar Bagasra, Kareem Heslop, Krystal Livingston, Keneisha Corbett, Amarachi O. Ejiawoko, Leanna Sealey
Journal: Cancer Research (2015)

Abstract Cancer therapies are generally non-specific for cancer cells and affect all cells in the body, resulting in severe side effects. We are working on an alternate method to present and treat cancer. Hypothesis: All replicating cells require energy in the forms of ATP and row material to reproduce. Cancer in a human body generally is the most energy consuming foci; therefore, it will be logical to down regulate the highest energy output pathways that do not harm the human being treated for a cancer. Two of the most prevalent cancers in are adenocarcinomas of prostate and breast. We hypothesized that if we treat cancer cells to a partial electron transport inhibitor that results in reduction in total ATP output it may significantly reduce cancer cell proliferation without interfering with normal functioning of other physiologic and immune functions. We chose Amygdalin (D-mandelonitrile-β-gentiobioside) which is found in seeds of prunasin family plants, such as peaches, apricots, almonds, apples, and other rosaceous plants and have been used as a traditional alternate medicine for treating terminal cancers and other illnesses. We evaluated the optimal dose that can inhibit various breast and prostate cancer cell lines as well two stem cell lines derived from neuroblastomas. We determine that cancer cell line and stem cell line proliferation rates were significantly inhibited 0.9 μM concentration of Amygdalin. This level of Amygdalin can be achieved by consuming 4-6 bitter almond and 2-3 apricot seed daily. In addition, we observed that Amygdalin induced apoptosis in the prostate and breast cancer cell lines. Citation Format: Omar Bagasra, Kareem Heslop, Krystal Livingston, Keneisha Corbett, Amarachi O. Ejiawoko, Leanna Sealey. Inhibitory Effect of Partial Electron Decoupling Agents as an Alternate Therapy for Cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5568. doi:10.1158/1538-7445.AM2015-5568
The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL)
Authors: Musa Yilmaz, Hagop M. Kantarjian, Farhad Ravandi, Jeffrey L. Jorgensen, Sa Wang, Guillermo Garcia-Manero, Jorge E. Cortes, Koji Sasaki, Courtney DiNardo, Tapan Kadia, Jane Autry, Rebecca Garris, Elias Jabbour
Journal: Blood (2015)
Synergy of Sequential and Concurrent Administration of a Deglycosylated Ricin A Chain-Containing Combined Anti-CD19 and Anti-CD22 Immunotoxin (Combotox) and Cytarabine in a Murine Model of Advanced Acute Lymphoblastic Leukemia
Authors: Stefan K Barta, Yiyu Zou, John Schindler, Tushar Bhagat, Victor Ghetie, Ellen S Vitetta, Amit Verma
Journal: Blood (2011)
Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment
Authors: Meletios A. Dimopoulos, Maria Roussou, Evangelos Terpos, Erasmia Psimenou, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Despoina Kalapanida, Marios Bakogeorgos, Despoina Mparmparoussi, Theodoros P. Vassilakopoulos, Dimitra Gika, Charis Matsouka, Ioannis Boletis, Kostas Konstantopoulos, Efstathios Kastritis
Journal: Blood (2014)
Correlation of Different Responses to Imatinib on Survival of Patients (pts) with Chronic Myelogenous Leukemia (CML) in Accelerated (AP) and Blast Phase (BP).
Authors: Etsuko Aoki, Hagop Kantarjian, Susan O’Brien, Mary Beth Rios, Farhad Ravandi, Srdan Verstovsek, Guillermo Garcia-Manero, Jianqin Shan, Jorge Cortes
Journal: Blood (2005)
Clinical Usefulness and Prognostic Value of Interim PET/CT for the Treatment of Peripheral T Cell Lymphomas.
Authors: Deok-Hwan Yang, Jung-Joon Min, Ho-Chun Song, Yong Yeon Jeong, Soo-Young Bae, Jae-Sook Ahn, Yeo-Kyeoung Kim, Hee-Seung Bom, Ik-Joo Chung, Hyeoung Joon Kim, Je-Jung Lee
Journal: Blood (2010)
Inhibition of TET2 Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine Disturbs Myelopoiesis and Granulo-Monocytic Differentiation.
Authors: Elodie Pronier, Carole Almire, Barbara da Costa Reis Monte Mor, Audrey Simon, Aline Massé, Hayat Mokrani, Nicole Casadevall, Jean-Luc Ravanat, Eric Solary, William Vainchenker, Isabelle Plo, Francois Delhommeau
Journal: Blood (2010)
A Glyco-Optimized Anti-CD20 Antibody from the Aquatic Plant Lemna: Comparison of Pharmacokinetics, B-Cell Depletion and Complement Activation with Rituxan® in Cynomolgus Monkeys
Authors: John R Gasdaska, Jeff Regan, Steve Sherwood, Klaus-Peter Radtke, Bipin Dalmia, John E. Humphries, Lynn F Dickey
Journal: Blood (2008)
Initial Experience with the IMPROVE Trial-a Phase III Analgesic Trial for Hospitalized Sickle Cell Painful Episodes
Authors: Carlton Dampier, Wally R. Smith, Carrie Wager, Margaret Bell, James R. Eckman, Lewis L Hsu, Donna McClish, Sonja McKinlay, Caterina Minitti, Robert Molokie, Kim Smith-Whitley, Marilyn J. Telen, Debra Weiner, Scott Miller
Journal: Blood (2010)
Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities
Authors: Jennifer A. Woyach, Amy S. Ruppert, Kristie A. Blum, Jeffrey Alan Jones, Joseph M. Flynn, Amy J. Johnson, Michael R. Grever, John C. Byrd, Nyla A. Heerema
Journal: Blood (2010)
Osteonecrosis of the Jaw Related to Bisphosphonates Therapy in Multiple Myeloma and Metastatic Prostate Cancer Patients. A Latin American Report: An Adverse Event To Look For!!.
Authors: Brady Beltran, Luis Riva, Daniel del Carpio, Ivan Fernandez, Luis Vera, Rocio Reategui, Fernando Hurtado de Mendoza, Jorge Castillo, Antonio A. Carrasco-Yalan
Journal: Blood (2007)
5-Azacytosine (Azacytidine) and 2′-Deoxy-5-Azacytidine (Decitabine) Mediate Opposite Effects on NK Cell Anti-Tumor Reactivity
Authors: Benjamin J Schmiedel, Viktor Arélin, Matthias Krusch, Lothar Kanz, Helmut R Salih
Journal: Blood (2008)
Long-Term Complications (LTC) and Quality of Life (QOL) After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT),
Authors: Aline Clavert, Peric Zina, Xavier Cahu, Patrice Chevallier, Eolia Brissot, Florent Malard, Thierry Guillaume, Jacques Delaunay, Sameh Ayari, Viviane Dubruille, Beatrice Mahe, Nicolas Blin, Thomas Gastinne, Virginie Roland, Steven Le Gouill, Jean-Luc Harousseau, Philippe Moreau, Noel Milpied, Mohamad Mohty
Journal: Blood (2011)
Gene Expression Profiling Identifies IGFBP7 as a BAALC Co-Expressed Gene with a Functional Role in Acute Leukemia.
Authors: Sandra Heesch, Cornelia Schlee, Martin Neumann, Andrea Stroux, Andrea Kühnl, Stefan Schwartz, Torsten Haferlach, Nicola Goekbuget, Dieter Hoelzer, Wolf-Karsten Hofmann, Eckhard Thiel, Claudia D Baldus
Journal: Blood (2009)
Gene Expression Model of Survival and Transformation in Follicular Lymphoma (FL): A Study by the LLMPP.
Authors: N.A. Johnson, T. Nayar, S.S. Dave, G. Wright, A. Rosenwald, W.C. Chan, M. Bast, L.M. Rimsza, H. Holte, J. Delabie, J.M. Connors, A. Al-Tourah, L. Colomo, E. Campo, T.A. Lister, D. O’Shea, L.M. Staudt, Randy D. Gascoyne
Journal: Blood (2007)
Monocyte-Derived Dendritic Cells from HLA-Matched Allogeneic Donors Showed Superiority To Induce Leukemic Cell-Specific T Cells in Comparison to Leukemic Cell-Derived Dendritic Cells or Monocyte-Derived Dendritic Cells from AML Patients.
Authors: Je-Jung Lee, Bo-Hwa Choi, Myong-Suk Park, Deok-Hwan Yang, Yeo-Kyeoung Kim, Hyeoung-Joon Kim
Journal: Blood (2004)
Akt/PKB Activation-Induced Cytoplasmic Mislocalization of p27Kip1 Protein Is Mediated by Jab1 Shuttling in Human Myeloid Leukemia Cells.
Authors: Yoo-Hong Min, Ju In Eom, Ae Jin Choi, Jee Young Lee, Jin Seok Kim, Seung Tae Lee, June-Won Cheong
Journal: Blood (2004)
Allogeneic Genetically Modified T Cells (HSV-TK) As Adjunctive Treatment in Haploidentical Hematopoietic Stem-Cell Transplantation (haplo-HSCT) of Adult Patients with High-Risk Hematological Malignancies: A Pair-Matched Analysis from the Acute Leukemia Working Party of EBMT
Authors: Mohamad Mohty, Myriam Labopin, Andrea Velardi, Maria Teresa van Lint, Donald Bunjes, Benedetto Bruno, Stella Santarone, Johanna Tischer, Yener Koc, Depei Wu, Zafer Gulbas, Annalisa Ruggeri, Florent Malard, Simona Piemontese, Maria Teresa Lupo Stanghellini, Chiara Bonini, Claudio Bordignon, Fabio Ciceri, Arnon Nagler
Journal: Blood (2016)
Anagrelide Treatment and Cardiovascular Evaluation in 130 Patients with Essential Thrombocythemia (ET): Preliminary Report of the Registro Italiano Trombocitemia (RIT).
Authors: Luigi Gugliotta, A. Tieghi, S. Bulgarelli, G. Tortorella, R. Ciancia, P. R. Scalzulli, E. Cacciola, R. Cacciola, D. Rossi, E. Usala, M. Crugnola, A. Candoni, M. Giordano, A. Andriani, C. Santoro, R. Vimercati, M. Liberati, A. Sciorio, G. Specchia, V. Martinelli, G. Gaidano, M. G. Mazzucconi
Journal: Blood (2005)
Oral immunotherapy–induced gastrointestinal symptoms and peripheral blood eosinophil responses
Authors: Michael R. Goldberg, Arnon Elizur, Liat Nachshon, Michael Y. Appel, Michael B. Levy, Keren Golobov, Robert Goldberg, Miguel Stein, Marc E. Rothenberg, Yitzhak Katz
Journal: Journal of Allergy and Clinical Immunology (2016)
Junior doctors’ low morale is putting patients at risk, Royal College of Physicians warns
Authors: Abi Rimmer
Journal: BMJ (2016)

Patient safety is suffering as a result of poor staff morale and excessive stress, a survey of junior doctors has found.

On Thursday 1 December the Royal College of Physicians (RCP) published a report, Being a junior doctor. Experiences from the front line of the NHS , based on a survey of 498 junior doctors.1

The report said that junior doctors were experiencing high levels of stress because of rota gaps, poor access to basic facilities, and a growing workload. “One in four junior doctors say that their role has had a serious …
Early Occurrence of Therapy-Related Acute Myeloid Leukemia (t-AML) with Monocytic Differentiation with Trisomy 8 Cytogenetic Abnormality after Radioactive Iodine (RAI) Treatment for Papillary Thyroid Cancer
Authors: Oscar Boutros Lahoud, Dhakal Ajay, Abhinav B Chandra
Journal: Blood (2014)
Antithymocyte Globulin (ATG) for Graft-Versus-Host-Disease (GvHD) Prophylaxis In Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (allo-HCT): a Systematic Review and Meta-Analysis.
Authors: Ambuj Kumar, Asmita R Mhaskar, Mohamed Kharfan-Dabaja, Claudio Anasetti, Mohamad Mohty, Benjamin Djulbegovic
Journal: Blood (2010)
Double-Unit Cord Blood (CB) Transplantation (DCBT) Combined with Haplo-Identical CD34+ Selected Peripheral Blood Stem Cells (PBSC) Is Associated with Enhanced Neutrophil Recovery, Universal Haplo Rejection and Frequent Pre-Engraftment Syndrome
Authors: Matias Eugenio Sanchez, Doris M. Ponce, Emily J Lauer, Marissa N Lubin, Jonathan Barone, Courtney Byam, Parastoo B Dahi, Richard Meagher, Hugo Castro-Malaspina, Ann A. Jakubowski, Guenther Koehne, Esperanza B Papadopoulos, Miguel-Angel Perales, Craig S. Sauter, Roni Tamari, Andromachi Scaradavou, Nancy A. Kernan, Sergio Giralt, Richard J O'Reilly, Juliet N. Barker
Journal: Blood (2014)
Mechanisms of the BCR-Mediated CXCR4 Down-Regulation and Its Clinical Relevance in Chronic Lymphocytic Leukemia Progression
Authors: Christine Le Roy, Dominique Ledoux, Stephane Saint Georges, Maud Quettier, Marouane Boubaya, Stephanie Le Coquil, Vanessa Lauriente, Lionel Guittat, Vincent Levy, Florence Cymbalista, Nadine Varin-Blank
Journal: Blood (2015)
Erythropoietin Receptor Deficient Mice Have Impaired Voluntary Wheel-running Performance
Authors: Willem-Peter T. Ruifrok, B. D. Westenbrink, Irma Kuipers, Alexander H. Maass, Adriaan A. Voors, Dirk J. van Veldhuisen, Wiek H. van Gilst, Rudolf A. de Boer
Journal: Circulation (2008)
Genes Involved in Acute Leukemias Are Favored Targets of HIV Vector Integration
Authors: Jens U. Appelt, Frank A. Giordano, Marcel Zimmermann, Stephan Weinhard, Nadja Grund, Agnes Hotz-Wagenblatt, W. Jens Zeller, Heike Allgayer, Stefan Fruehauf, Stephanie Laufs
Journal: Blood (2007)
Myelomatous Pleural Effusion of Multiple Myeloma: Characteristics and Outcome.
Authors: Hyo Jung Kim, Dae Ro Choi, Gak-Won Yun, Eunkyung Park, Seok Jin Kim, Young Kyung Lee, Jong-Ho Won, Sung-Soo Yoon, Cheolwon Suh, Korean Multiple Myeloma Working Party
Journal: Blood (2009)
Clinical Significance of Arbekacin Sulfate for High-Risk Infections Among Patients with Hematological Malignancies
Authors: Katsuhiro Miura, Satomi Kiso, Masaru Nakagawa, Hiromichi Takahashi, Yoshito Uchino, Hitomi Kodaira, Noriyoshi Iriyama, Masashi Sakagami, Shimon Ohtake, Sumiko Kobayashi, Atsuko Hojo, Mai Yagi, Daisuke Kurita, Yujin Kobayashi, Machiko Kusuda, Yukio Hirabayashi, Yoshihiro Hatta, Masami Takei
Journal: Blood (2014)
Targeting Interleukin-2 to the Neovasculature Potentiates Rituximab‘s Activity Against Mantle Cell Lymphoma in Mice
Authors: Christoph Schliemann, Niklas Börschel, Christian Schwöppe, Rüdiger Liersch, Torsten Kessler, Martin Dreyling, Wolfram Klapper, Hans D. Menssen, Dario Neri, Wolfgang E. Berdel, Rolf M. Mesters
Journal: Blood (2012)
Autologous Non-Myeloablative Hematopoietic Stem Cell Transplantation for Refractory Systemic Vasculitis.
Authors: Laisvyde Statkute, Yu Oyama, Walter G. Barr, Jolita Satkus, Yvonne Loh, Larissa Verda, Richard K. Burt
Journal: Blood (2006)
Ferrochelatase Mutation Screening by Denaturing High Performance Liquid Chomatography in Idiopathic Acquired Sideroblastic Anemia (Refractory Anemia with Ringed Sideroblasts) and Erythrocytic Protoporphyria.
Authors: Kathleen A. Hecksel, Gordon W. Dewald, David P. Steensma
Journal: Blood (2005)
Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis (RARS-t): A Clinicopathological Entity with Questionable Pathogenesis
Authors: Anupma Nayak, Abha Goyal, Judith Brody, Peihong Hsu, Steven Savona, Rita Weiss, George Zervos
Journal: Blood (2008)
Reduction of Tregs with Expansion of Th1 Cells and Lack of IFN-γ Secretion by GPI Negative T-Cells In PNH
Authors: Shahram Kordasti, Modupe Elebute, Pilar Perez Abellan, Austin G Kulasekararaj, Janet Hayden, Azim Mohamedali, Ghulam J. Mufti
Journal: Blood (2010)
Hospitals overwhelmed with patients after “thunderstorm asthma” hits Melbourne
Authors: Michael Woodhead
Journal: BMJ (2016)

At least four people have died and thousands have been taken to hospital with respiratory problems after a “thunderstorm asthma” event in Melbourne on Monday 21 November.

Ambulance services and hospital emergency departments were overwhelmed by the unprecedented incident, believed to have been caused by a surge in pollen levels, triggering allergic asthma in vulnerable people.

Victoria’s health department said that since the event more than 8500 patients had presented to hospitals with respiratory problems, of whom 60 were still receiving treatment and five were in a critical condition.

Among the dead were a 35 year old man, a 20 year old female student, and an 18 year old high school student.

Respiratory physicians …
ATIM-11. PHASE 2 TRIAL OF SL-701, A NOVEL IMMUNOTHERAPY COMPRISED OF SYNTHETIC SHORT PEPTIDES AGAINST GBM TARGETS IL-13Rα2, EphA2, AND SURVIVIN, IN ADULTS WITH SECOND-LINE RECURRENT GBM: INTERIM RESULTS
Authors: David Reardon, David Peereboom, Burt Nabors, Karen Fink, Surasak Phuphanich, Tom Mikkelsen, Erin Dunbar, Michael Badruddoja, David Schiff, Frank Lieberman, David Tran, Michael Schulder, Nicholas Butowski, Lynn Ashby, Christopher Moertel, Fabio Iwamoto, Jonathan Sherman, Janice Chen, Peter McDonald, Enrique Poradosu, Christopher Brooks, Shay Shemesh, Jeffrey Raizer
Journal: Neuro-Oncology (2016)

SL-701 is a novel immunotherapy comprised of synthetic short peptides designed to elicit an immune response against three overexpressed GBM targets: interleukin-13 receptor alpha-2 (IL-13Rα2), EphrinA2 (EphA2), and Survivin. We report preliminary data from an ongoing multicenter, 2-stage Phase 2 clinical trial of SL-701 in HLA-A2 positive adults with first recurrence of GBM. Patients had to have KPS > 60, age > 18, and failed standard RT/TMZ. In Stage 1, SL-701 with adjuvants GM-CSF and imiquimod is administered biweekly for 6 months, then every 28 days thereafter. In Stage 2, SL-701 with the adjuvant poly-ICLC is administered biweekly with bevacizumab (10 mg/kg). Primary objectives: 1) safety and tolerability 2) investigator assessed objective response rate (ORR) using RANO criteria and 3) survival rate at 12 months. As of 5/17/16, 58 patients (46 in Stage 1 and 12 in Stage 2) received SL-701. Accrual for Stage 1 is complete. Stage 2 accrual is ongoing. Median age is 55 years (range: 23–74), median KPS is 90, and 67% are male. Patients received a median of 4 doses. The most frequent grade 3–4 treatment-related adverse events (TRAEs) were fatigue (n = 1; 1.7%) and altered mental status (n = 1, 1.7%). Among 30 evaluable patients in Stage 1, there was 1 partial response (PR) (33+ weeks duration, ongoing) and 15 stable diseases (SD) (median duration: 8 weeks; range: 8–42+ weeks, ongoing). Of the 4 evaluable patients in Stage 2 to date, there has been 1 PR (8+ weeks duration, ongoing) and 3 SD (median duration: 8 weeks; range: 5–8+ weeks, ongoing). SL-701 plus adjuvants GM-CSF/imiquimod or poly-ICLC and bevacizumab is well-tolerated. Patients are being followed for response, SD, PFS, and OS. Updated study data will be presented.